97 related articles for article (PubMed ID: 7516378)
1. [Pharmacological combinations in the treatment of benign prostatic hypertrophy].
Di Silverio F; D'Eramo G; Flammia GP; Buscarini M; Frascaro E; Mariani M; Sciarra A
J Urol (Paris); 1993; 99(6):316-20. PubMed ID: 7516378
[TBL] [Abstract][Full Text] [Related]
2. [Conservative treatment of benign prostatic hyperplasia (author's transl)].
Schoenenberger A; Hauri D
Ther Umsch; 1982 Apr; 39(4):260-7. PubMed ID: 6179177
[No Abstract] [Full Text] [Related]
3. [Antiandrogen therapy of benign prostatic hyperplasia--review of the agents evaluation of the clinical results].
Kanimoto Y; Okada K
Hinyokika Kiyo; 1991 Nov; 37(11):1423-8. PubMed ID: 1722627
[TBL] [Abstract][Full Text] [Related]
4. 4. Steroid pathophysiology of BPH. Correlative morphological and biochemical investigations on the stromal tissue of the human prostate.
Bartsch G; Daxenbichler G; Rohr HP
J Steroid Biochem; 1983 Jul; 19(1A):147-54. PubMed ID: 6193337
[TBL] [Abstract][Full Text] [Related]
5. Current treatment of BPH.
Roylance P; Gibelin B; Espié J
Biomed Pharmacother; 1995; 49(7-8):332-8. PubMed ID: 8562858
[TBL] [Abstract][Full Text] [Related]
6. [Benign hypertrophy of the prostate: which treatment, for whom?].
Schulman C
Rev Med Brux; 1999 Sep; 20(4):A212-8. PubMed ID: 10523895
[TBL] [Abstract][Full Text] [Related]
7. [Current drug therapy of benign prostatic hyperplasia].
Schmidbauer CP; Madersbacher S
Wien Med Wochenschr; 1996; 146(8):161-4. PubMed ID: 8767400
[TBL] [Abstract][Full Text] [Related]
8. The effect of antiestrogen, antiandrogen, and the prolactin inhibitor 2 bromo-alpha-ergocriptine on the stromal tissue of human benign prostatic hyperplasia. Correlation of stereological data and plasma hormones.
Bartsch G; Oberholzer M; Rohr HP
Invest Urol; 1981 Jan; 18(4):308-12. PubMed ID: 6161105
[TBL] [Abstract][Full Text] [Related]
9. Role of alpha blockers in the treatment of BPH: a critical review of clinical results.
Von Heland M; Casale P
Arch Esp Urol; 1994 Nov; 47(9):873-81; discussion 881-2. PubMed ID: 7530943
[TBL] [Abstract][Full Text] [Related]
10. Long-term results of medical treatment in benign prostatic hyperplasia.
Kim CI; Chang HS; Kim BK; Park CH
Urology; 2006 Nov; 68(5):1015-9. PubMed ID: 17095071
[TBL] [Abstract][Full Text] [Related]
11. [Monitoring the effectiveness of conservative treatment of benign prostatic hypertrophy by means of uroflowmetry].
Tunn U; Senge T
Z Urol Nephrol; 1978 Aug; 71(8):521-8. PubMed ID: 83057
[TBL] [Abstract][Full Text] [Related]
12. The role of combination medical therapy in benign prostatic hyperplasia.
Greco KA; McVary KT
Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
[TBL] [Abstract][Full Text] [Related]
13. [Novel therapeutics strategies in benign hypertrophy of prostate management].
Roumeguère T
Rev Med Brux; 2005 Sep; 26(4):S407-11. PubMed ID: 16240894
[TBL] [Abstract][Full Text] [Related]
14. Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia.
Chon JK; Borkowski A; Partin AW; Isaacs JT; Jacobs SC; Kyprianou N
J Urol; 1999 Jun; 161(6):2002-8. PubMed ID: 10332490
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician.
Chapple CR
BJU Int; 2004 Sep; 94(5):738-44. PubMed ID: 15329091
[TBL] [Abstract][Full Text] [Related]
16. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia.
Debruyne F; Barkin J; van Erps P; Reis M; Tammela TL; Roehrborn C;
Eur Urol; 2004 Oct; 46(4):488-94; discussion 495. PubMed ID: 15363566
[TBL] [Abstract][Full Text] [Related]
18. [Drug therapy for benign prostatic syndrome (BPS)].
Berges R
Aktuelle Urol; 2006 Sep; 37(5):351-62. PubMed ID: 17004180
[TBL] [Abstract][Full Text] [Related]
19. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE.
Roehrborn CG
BJU Int; 2008 Mar; 101 Suppl 3():17-21. PubMed ID: 18307681
[TBL] [Abstract][Full Text] [Related]
20. [Hormonal therapy of benign prostatic hyperplasia].
Horninger W; Bartsch G
Urologe A; 1995 Jan; 34(1):9-15. PubMed ID: 7533450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
